Pancreatic cancer: An update

Current Oncology Reports

Volumn 9, Issue 3, 2007, Pages 170-176

  Kindler, Hedy Lee ^a   Bylow, Kathryn ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; EXATECAN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GEMCITABINE PLUS OXALIPLATIN; GEMOX; IRINOTECAN; MARIMASTAT; OXALIPLATIN; PEMETREXED; PLACEBO; TANOMASTAT; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG ERUPTION; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKEMIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PNEUMONIA; REVIEW; STANDARDIZATION; STATISTICAL SIGNIFICANCE; STOMATITIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; QUINAZOLINES;

EID: 34248401996     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-007-0018-z     Document Type: Review

References (35)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2006. CA J Clin 2006, 56:106-130.
2. Gloeckler Ries LA, Reichman ME, Lewis DR, et al.: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003, 8:541-552.
3. Burris HA III, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
4. Friberg G, Kindler HL: Chemotherapy for advanced pancreatic cancer: past, present, and future. Curr Oncol Rep 2005, 7:186-195.
5. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] [abstract]. Proc ASCO 2005, 23(16S):1s.
6. Cunningham D, Chau I, Stocken C, et al.: Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 2005, 3(Suppl):S4.
7. Poplin E, Levy DE, Berlin J, et al.: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201) [abstract]. Proc ASCO 2006, 24:LBA4004.
8. Phase III study of Avastin in advanced pancreatic cancer does not meet primary endpoint [press release]. South San Francisco, CA: Genentech; June 26, 2006.
9. Moore MJ, Hamm J, Dancey J, et al.: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3296-3302.
10. Bramhall SR, Rosemurgy A, Brown PD, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447-3455.
11. Cheverton P, Friess H, Andras C, et al.: Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC) [abstract]. Proc ASCO 2004, 23:314s.
12. Berlin JD, Catalano P, Thomas JP, et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002, 20:3270-3275.
13. Riess H, Helm A, Niedergethmann M, et al.: A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer [abstract]. Proc ASCO 2005, 23:310s.
14. Herrmann R, Bodoky G, Ruhstaller T, et al.: Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc ASCO 2005, 23(16S):310s.
15. Oettle H, Richards D, Ramanathan RK, et al.: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005, 16:1639-1645.
16. Rocha Lima CM, Green MR, Rotche R, et al.: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004, 22:3776-3783.
17. Abou-Alfa GK, Letourneau R, Harker G, et al.: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006, 24:4441-4447.
18. Heinemann V, Quietzsch D, Gieseler F, et al.: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006, 24:3946-3952.
19. Louvet C, Labianca R, Hammel P, et al.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23:3509-3516.
20. Tobita K, Kijima H, Dowaki S, et al.: Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 2003, 11:305-309.
21. Durkin AJ, Osborne DA, Yeatman TJ, et al.: EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma. J Surg Res 2006, 135:195-201.
22. Dragovich T, Hubermann M, von Hoff DD, et al.: Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol 2006 (Epub ahead of print),
23. Kwak EL, Jankowski J, Thayer SP, et al.: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006, 12:4283-4287.
24. Immervol H, Hoem D, Kugarajh K, et al.: Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 2006, 448:788-796.
25. Grubbs SS, Grusenmeyer PS, Petrelli NJ, et al.: Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer [abstract]? Proc ASCO 2006, 24:313s.
26. Abbruzzese JL, Grunewald R, Weeks EA, et al.: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991, 9:491-498.
27. Tempero M, Plunkett W, Ruiz V, et al.: Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21:3402-3408.
28. Seo Y, Baba H, Fukuda T, et al.: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88:2239-2245.
29. Solorzano CC, Baker CH, Bruns CJ, et al.: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 2001, 16:359-370.
30. Bruns CJ, Shrader M, Harbison MT, et al.: Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 2002, 102:101-108.
31. Kindler HL, Friberg G, Singh DA, et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005, 23:8033-8040.
32. Kindler HL: Clinical trials broadcast: CALGB 80303, A randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer. Clin Adv Hematol Oncol 2005, 3:420-422.
33. Xiong HQ, Rosenberg A, LoBuglio A, et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multi-center phase II trial. J Clin Oncol 2004, 22:2610-2616.
34. Tonra JR, Deevi DS, Corcoran E, et al.: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006, 12:2197-2207.
35. Kindler HL, Bylow KA, Hochster H, et al.: A randomized phase II study of bevacizumab and gemcitabine plus cetuximab or erlotinib in patients with advanced pancreatic cancer: A preliminary analysis [abstract]. Proc ASCO 2006, 24:188s.